TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from Prenetics Group ( (PRE) ).
On November 18, 2025, Prenetics Global Limited’s CEO and co-founder, Danny Sheng Wu Yeung, purchased 20,118 shares of the company’s Class A Ordinary Shares at $12.02 per share, totaling approximately $242,000. This acquisition increases his total holdings to 76,412 shares, reflecting a significant personal investment in the company and potentially signaling confidence in its future performance.
The most recent analyst rating on (PRE) stock is a Hold with a $11.50 price target. To see the full list of analyst forecasts on Prenetics Group stock, see the PRE Stock Forecast page.
Spark’s Take on PRE Stock
According to Spark, TipRanks’ AI Analyst, PRE is a Neutral.
The overall stock score of 42 reflects significant profitability and cash flow challenges, as well as bearish technical indicators. The company’s strong equity base provides some financial stability, but the negative P/E ratio and lack of dividend yield highlight ongoing financial struggles.
To see Spark’s full report on PRE stock, click here.
More about Prenetics Group
Prenetics Global Limited is a leading health sciences company known for its IM8 premium health and longevity brand.
Average Trading Volume: 139,752
Technical Sentiment Signal: Buy
Current Market Cap: $166.3M
See more data about PRE stock on TipRanks’ Stock Analysis page.